Rheumatology Network's Top 5: December 10, 2021
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 10, 2021.
Rheumatoid Arthritis Quiz: Drug-Free Remission
Rheumatoid arthritis often requires long-term treatment with disease-modifying antirheumatic drugs (DMARDs), but tapering and even cessation of DMARDs can be considered for patients in remission. Test your knowledge of use of DMARDs in patients in remission with this quiz.
Click the image to view the story.
AbbVie Updates Upadacitinib Prescription Guidelines Amidst Safety Concerns
Selective Janus kinase (JAK) inhibitor, upadacitinib, is now intended for adults with moderate-to-severe rheumatoid arthritis (RA) who have had inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker.
Click the image to view the story.
Overdrive Podcast: Impact of COVID-19 on Quality of Life of Patients With Rheumatic Disease
On this month's episode of Overdrive, Rheumatology Network interviewed Courtney Wells, PhD, MPH, MSW, to discuss the impact of COVID-19 on the quality of life of patients with rheumatic conditions, focusing on perceived risk and decision making.
Click the image to view the story.
Inflammatory Disease Not Associated With Increased Alzheimer’s Disease Risk
Previous studies examining whether inflammatory disease was associated with an increased risk of Alzheimer's disease yielded mixed results.
Click the image to view the story.
Roy Fleischmann, MD: Efficacy of Olokizumab for Rheumatoid Arthritis Treatment
Roy Fleischmann, MD, explores the successful results of the novel IL-6 inhibitor, olokizumab, from 2 randomized clinical trials of the phase 3 global research program CREDO.
Click the image to view the story.
